Neopharmed Gentili S.p.A.
Neopharmed Gentili S.p.A., a prominent player in the pharmaceutical industry, is headquartered in Italy and operates extensively across Europe and beyond. Founded in 1992, the company has established itself as a leader in the development and distribution of innovative healthcare solutions, focusing on prescription medicines, over-the-counter products, and dietary supplements. With a commitment to quality and efficacy, Neopharmed Gentili offers a diverse portfolio of core products that cater to various therapeutic areas, including oncology, cardiology, and infectious diseases. The company is recognised for its rigorous research and development processes, which ensure that its offerings meet the highest standards of safety and effectiveness. Notably, Neopharmed Gentili has achieved significant milestones in expanding its market presence and enhancing its product range, solidifying its position as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Neopharmed Gentili S.p.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Neopharmed Gentili S.p.A.'s score of 13 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Neopharmed Gentili S.p.A.'s reported carbon emissions
In 2023, Neopharmed Gentili S.p.A. reported total carbon emissions of approximately 1,898,490 kg CO2e. This figure includes 679,440 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 240,050 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Additionally, the company recorded 999,000 kg CO2e in Scope 3 emissions, which cover all other indirect emissions in the value chain. Comparatively, in 2022, the company emitted about 1,929,360 kg CO2e, with 712,620 kg CO2e from Scope 1, 237,740 kg CO2e from Scope 2, and 999,000 kg CO2e from Scope 3. This indicates a slight reduction in total emissions from 2022 to 2023. Despite these figures, Neopharmed Gentili S.p.A. has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or any formal climate pledges. The absence of defined reduction strategies suggests a need for further commitment to climate action within the pharmaceutical industry context.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 712,620 | 000,000 |
| Scope 2 | 303,920 | 000,000 |
| Scope 3 | 999,000 | 000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Neopharmed Gentili S.p.A. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
